Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Medical World News

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

Alopecia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

COPD

COVID-19

Cardiovascular

Cholangiocarcinoma

Chronic Kidney Disease

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Digital Health

Duchenne Muscular Dystrophy

Employers

Epilepsy

Gastroenterology

Gene Therapy

Heart Failure

Hemophilia

Immuno-Oncology

Infectious Disease

Inflammation

Leukemia and Lymphoma

Liver

Lung Cancer

Lupus

Major Depressive Disorder

Medicare

Multiple Myeloma

Multiple Sclerosis

Myasthenia Gravis

Myelodysplastic Syndromes

Non-Small Cell Lung Cancer

Oncology

Ophthalmology

Ovarian Cancer

Parkinson Disease

Population Health

Prostate Cancer

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Rare Disease

Reimbursement

Respiratory

Rheumatology

Skin Cancer

Sleep

Spinal Muscular Atrophy

Type 1 Diabetes

Vaccines

Women's Health

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

eNewsletter

Articles

If finalized, these proposals will generally take effect on January 1, 2025, unless otherwise noted. 

HHS Proposes Keeping Same Risk Adjustment Policies for 2025, With Some Exceptions 

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Patients with diabetic macular edema could be treated with brolucizumab with as much effectiveness as aflibercept.

Brolucizumab as Effective as Aflibercept in Macular Edema Treatment

A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis. 

Disease-Modifying Antirheumatic Drugs Linked to Decreased Risk for Autoimmune Thyroid Disease

The Biden administration plans to utilize the Defense Production Act to boost essential medicine manufacturing; a landmark case challenges Texas abortion laws; reports of the BA.2.86 variant of SARS-CoV-2 have nearly tripled in the United States.

What We’re Reading: Biden Plans to Boost Domestic Drug Production; Abortion Laws and Pregnancy Complications; Surge in BA.2.86 COVID-19

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Rebecca K. Butler, ScM

Articles